Evidence map›Paper›PMID 34406609›Full record

ArticleActa neurologica Belgica2022

Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.

P Storch, P Burow, B Möller, T Kraya, S Heintz, N Politz, S Naegel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neurologica Belgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

P Storch *Headache Center Jena, Department of Neurology, University Hospital Jena, Am Klinikum 1, 07747 , Jena, Germany.
P Burow *Headache Center Halle, Department of Neurology, University Hospital Halle, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. philipp.burow@uk-halle.de.ORCID http://orcid.org/0000-0001-5730-0731
B MöllerHeadache Center Jena, Department of Neurology, University Hospital Jena, Am Klinikum 1, 07747 , Jena, Germany.
T KrayaDepartment of Neurology, Hospital St. Georg, Delitzscher Str. 141, 04129 , Leipzig, Germany.
S HeintzHeadache Center Halle, Department of Neurology, University Hospital Halle, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.
N PolitzHeadache Center Jena, Department of Neurology, University Hospital Jena, Am Klinikum 1, 07747 , Jena, Germany.
S NaegelHeadache Center Halle, Department of Neurology, University Hospital Halle, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany.
Jena University Hospital · DEUniversity Hospital in Halle · DEKlinikum St. Georg · DE

Funding

Novartis Pharma Lecture feesNovartis Pharma lecture fees, 1 research grant
6 · The paper itself

Abstract

Erenumab is a monoclonal antibody, targeted against the calcitonin gene-related peptide (CGRP) receptor. Clinical studies have demonstrated prophylactic efficacy in both episodic (EM) and chronic migraine (CM). The aim of the present study is to evaluate the efficacy of treatment in tertiary headache centers under real-life conditions. In a retrospective analysis, the period of 3 months before and after initiation of erenumab therapy was compared. Relevant parameters (headache days, headache intensity, headache duration, acute medication, previous prophylaxis treatments) were collected from medical charts of all migraine patients (N = 82) who started treatment with erenumab between November 1st 2018 and May 1st 2019 at two tertiary headache centers in Germany. The sample included 68 female (82.9%) and 14 male patients aged between 22 and 78 years (mean 51.1 years, SD 10.5 years). Of these patients, 57.3% met the criteria for CM and 56.9% overused acute medication. Under therapy with erenumab, a significant reduction of headache days was observed from the first month on. The effect was most pronounced in the third month with a decrease in monthly headache days from 16.6 to 11.6 days (p < 0.001). There was also a significant reduction in reported headache intensity (p = 0.004) and average duration of headache attacks (p = 0.016). The 50% responder rate in patients with CM was lower in the first month compared to EM but then increased similarly to EM. Patients with medication overuse (MO) also responded to the therapy. There was a reduction in medication overuse from 57% at baseline to 29% after therapy (p = 0.011). Overall, a positive result of treatment with erenumab can be shown in a highly selected sample with severely affected migraine patients and a refractory course prior to treatment. This re-confirms the clinical trial data also for this highly selected group.

Indexed as

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersAdultAgedAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHeadacheHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistserenumabCGRP antibodyErenumabMigraineMonoclonal antibodyProphylaxisReal-life data

Identifiers

PMID34406609
PMCPMC9300569
OpenAlexW3195209130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.